1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

From the 1Mayo Clinic, Jacksonville, Florida, 2Yale University School of Medicine, New
Haven, Connecticut, 3Cleveland Clinic Lerner College of Medicine of Case Western …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

A thrombin-like serine protease, jararassin-I, was isolated from the venom of Bothrops
jararaca. The protein was obtained in high yield and purity by a single chromatographic step …

Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial
fibrillation monitoring. Data from stroke registries show that both unknown and untreated or …

clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

Abstract In 2013, the European Heart Rhythm Association (EHRA) published a Practical
Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation …

While there is a clear clinical benefit of oral anticoagulation in patients with atrial fibrillation
(AF) and venous thromboembolism (VTE) in reducing the risks of thromboembolism, major …